Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Significant regulatory milestone marks advancement into clinical-stage development of next-generation RNAi therapy featuring an innovative, integrated systemic treatment delivery approach targeting...
-
ADARx Pharmaceuticals Expands Leadership Team with Appointment of Healthcare Investment Banking Veteran Ryan Fisk as CFO and CBO
-
The goal is to strengthen our intellectual property and to better understand how PRP technology can overcome resistant tumors and age-related diseases.
-
Significant regulatory milestone marks advancement into clinical-stage development of next-generation RNAi therapy featuring an innovative, integrated systemic treatment delivery approach targeting...
-
Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo ...
-
New senior executives bring significant biopharma experience as Persica moves to next phase of its development London, UK, 23 March 2026 - Persica Pharmaceuticals Limited (Persica), a clinical stage...
-
Beim Biotech & Finance Day auf der analytica trifft Life-Science-Unternehmertum auf Finanzierungswissen und Kapital.
-
ASIPP presentation follows publication of positive data from PP353 Phase 1b Modic Trial in The Lancet’s eClinicalMedicine London, UK, 19 March 2026 - Persica Pharmaceuticals Limited (Persica), a...
-
SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway...
-
Issued on behalf of Avaí Bio, Inc. Companies mentioned in this article: Avaí Bio (OTCQB: AVAI), FibroBiologics (NASDAQ: FBLG), Fate Therapeutics (NASDAQ: FATE), Mesoblast (NASDAQ: MESO), Longeveron...